MENU

SNDX Stock Syndax Pharmaceuticals (SNDX, $16.45) Moving Average Convergence Divergence (MACD) Histogram turned positive on October 7, 2025

A.I.dvisor
at Tickeron.com
Loading...
SNDX - Syndax Pharmaceuticals
MACD signal
Bullish Trend
Odds of UP Trend
Tickeron
MACD signal
Price: $16.45
Daily change: +$0.05 (+0.3%)
Daily volume: 1.5M
Capitalization: $1.4B
Industry: Biotechnology
This is a Bullish indicator signaling SNDX's price could rise from here. Traders may explore going long the stock or buying call options. A.I. dvisor identified 41 similar cases where SNDX's MACD histogram became positive, and of them led to successful outcomes. Odds of Success:

SNDX's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for SNDX turned positive on October 07, 2025. Looking at past instances where SNDX's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 03, 2025. You may want to consider a long position or call options on SNDX as a result. In of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The 50-day moving average for SNDX moved above the 200-day moving average on September 15, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SNDX advanced for three days, in of 286 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for SNDX moved out of overbought territory on September 08, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNDX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

SNDX broke above its upper Bollinger Band on October 06, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for SNDX entered a downward trend on October 01, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SNDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.025) is normal, around the industry mean (23.487). P/E Ratio (0.000) is within average values for comparable stocks, (54.584). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.216). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (18.248) is also within normal values, averaging (349.245).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
SNDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. SNDX showed earnings on August 04, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

a developer of biopharmaceuticals for novel cancer therapies

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
35 Gatehouse Drive
Phone
+1 781 419-1400
Employees
184
Web
https://www.syndax.com